Predict your next investment

Corporation
HEALTHCARE | Drug Development
symphogen.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$364.16M

About Symphogen

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market. The company has advanced the frontier of antibody discovery by creating well-characterized antibody mixtures that address multiple oncology targets in a single drug product. The company has matured its pipeline, currently has two product candidates in the clinic, and is researching promising novel immuno-oncology opportunities.On April 3, 2020, Symphogen was acquired by Servier. Terms of the transaction were not disclosed.

Symphogen Headquarter Location

Pederstrupvej 93

Ballerup, DK-2750,

Denmark

+45 4526 5050

Latest Symphogen News

BerGenBio announces leadership changes

Sep 15, 2021

BerGenBio announces leadership changes BerGenBio has announced the appointment of Martin Olin as new Chief Executive Officer from 8 September 2021. Following twelve years as CEO of BerGenBio, Richard Godfrey has decided to step down as CEO of the company with immediate effect to pursue other business interests. “I have thoroughly enjoyed my past twelve years at BerGenBio and will keenly watch the progress with bemcentinib as it progresses through the exciting next steps. Now is a natural time for me to hand over to Martin. I wish the Board and whole team every success for the future,” says Richard Godfrey. Rune Skeie, Chief Financial Officer of BerGenBio, assumed the role of interim CEO until 8 September 2021. Martin Olin Martin Olin brings more than 20 years of executive experience in the pharmaceutical and biotechnology industry to BerGenBio. He previously served as CEO of Symphogen, a biotechnology company focused on the development of protein drugs based on recombinant monoclonal antibody mixtures, acquired by Servier in 2020. Before joining Symphogen in 2012, Olin was a senior partner with SLS Invest, a Scandinavian based healthcare focused private equity fund. Previously, he held managerial positions in Novo Nordisk including Finance Director, EMEA. Most recently he has served as Managing Partner of Nordic Eye, a Copenhagen based Venture Capital firm. “BerGenBio has pioneered the understanding of AXL biology and the potential of AXL inhibition as a cornerstone therapy for the treatment of serious diseases. I am very excited to join the Company and look forward to working with the board and team to continue the progression of our lead candidate bemcentinib, as well as the pipeline of drug candidates, through further clinical development and ultimately to the patients we believe will benefit from them,” says Martin Olin, Chief Executive Officer of BerGenBio. Photo of Martin Olin

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Symphogen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Symphogen is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,137 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Symphogen Patents

Symphogen has filed 27 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/30/2016

6/15/2021

Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Monoclonal antibodies for tumors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/30/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/15/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Immune system, Immunology, Monoclonal antibodies, Monoclonal antibodies for tumors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Symphogen Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Symphogen Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.